Wide Ranks

ARTV

Artiva Biotherapeutics, Inc.

12.60

Top Statistics
Market Cap 306 M Forward PE -4.83 Revenue Growth 0.00 %
Current Ratio 11.33 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -2.98 Enterprise / Revenue 67.04 Price To Sales Trailing12 Months 117.66
Profitability
Profit Margins 0.00 % Operating Margins -2344.68 %
Balance Sheet
Total Cash 146 M Total Cash Per Share 6.04 Total Debt 14 M
Total Debt To Equity 7.45 Current Ratio 11.33 Book Value Per Share 8.28
All Measures
Short Ratio 1296.00 % Message Board Id finmb_672643147 Shares Short Prior Month 940524
City San Diego Uuid 8e252093-be09-3198-b7f1-62334b202526 Previous Close 12.21
First Trade Date Epoch Utc 1 B Book Value 8.28 Total Debt 14 M
Volume 25777 Price To Book 1.52 Fifty Two Week Low 9.68
Total Cash Per Share 6.04 Total Revenue 2 M Shares Short Previous Month Date 1 B
Target Median Price 22.00 Max Age 86400 Recommendation Mean 1.20
Sand P52 Week Change 0.3133 Operating Margins -2344.68 % Target Mean Price 21.25
Net Income To Common -61276000 Ask 12.85 Short Percent Of Float 0.0388
Implied Shares Outstanding 24 M Last Fiscal Year End 1 B Trailing Peg Ratio None
Average Daily Volume10 Day 49630 Average Volume10days 49630 Total Cash 146 M
Next Fiscal Year End 1 B Revenue Per Share 0.4850 Held Percent Insiders 0.2064
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 12.21 Target Low Price 18.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 12.58 Open 12.37 Dividend Yield 0.00 %
State CA Time Zone Short Name EST Trailing Eps -2.48
Day Low 12.37 Address1 5505 Morehouse Drive Shares Outstanding 24 M
Price Hint 2 Target High Price 23.00 Website https://www.artivabio.com
52 Week Change 0.0500 Average Volume 135056 Forward Eps -3.45
Recommendation Key strong_buy Compensation As Of Epoch Date 1 B Quick Ratio 1113.70 %
Is_sp_500 False Regular Market Day High 12.92 Profit Margins 0.00 %
Debt To Equity 7.45 Fifty Two Week High 17.31 Day High 12.92
Shares Short 935773 Regular Market Open 12.37 Industry Key biotechnology
Bid 12.35 Earnings Growth 0.00 % Enterprise To Revenue 67.04
Revenue Growth 0.00 % Shares Percent Shares Out 0.0385 Operating Cashflow -51057000
Currency USD Time Zone Full Name America/New_York Market Cap 306 M
Is_nasdaq_100 False Zip 92121 Quote Type EQUITY
Industry Biotechnology Long Name Artiva Biotherapeutics, Inc. Regular Market Day Low 12.37
Held Percent Institutions 0.8904 Current Price 12.60 Address2 Suite 100
Enterprise To Ebitda -2.98 Financial Currency USD Current Ratio 11.33
Gross Margins 100.00 % Industry Disp Biotechnology Number Of Analyst Opinions 4
Country United States Float Shares 4 M Two Hundred Day Average 11.96
Enterprise Value 174 M Price To Sales Trailing12 Months 117.66 Forward PE -4.83
Regular Market Volume 25777 Ebitda -58574000 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers.

The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.

It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate.

The company was incorporated in 2019 and is headquartered in San Diego, California.